SCHEMBL4809787

SCHEMBL4809787

NC(Cc1cc(Br)c(OCc2ccccc2F)c(Br)c1)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.64
PDCD1 Q15116 1/20 0.51
CD274 Q9NZQ7 1/20 0.51
SLC1A5 Q15758 1/20 0.49
THRB P10828 4/20 0.47
THRA P10827 3/20 0.47
MAPT P10636 4/20 0.47
LMNA P02545 1/20 0.47
ALPG P10696 1/20 0.47
PPARG P37231 1/20 0.46
SLC7A5 Q01650 2/20 0.46
ALPI P09923 1/20 0.46
PKM P14618 1/20 0.46
PTGS1 P23219 1/20 0.46
XIAP P98170 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 2/20 0.45
GAA P10253 2/20 0.45
BLM P54132 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4815513 0.80 SLC1A5 (0.49) PTPN1PDCD1CD274SLC1A5THRB
SCHEMBL6553667 0.80 THRB (0.49) PTPN1PDCD1CD274THRBTHRA
SCHEMBL4896380 0.79 THRB (0.73) THRBTHRAMAPTLMNAALPG
SCHEMBL4812326 0.78 THRA (0.64) PDCD1CD274THRBTHRAPPARG
SCHEMBL4899376 0.78 THRA (0.64) PDCD1CD274THRBTHRAPPARG
SCHEMBL4817169 0.76 THRA (0.51) THRBTHRAPPARGSLC7A5ALPI
SCHEMBL4808172 0.76 THRA (0.67) SLC1A5THRBTHRAMAPTALDH1A1
SCHEMBL4818194 0.75 SLC7A5 (0.53) PDCD1CD274THRBTHRAMAPT
SCHEMBL4810919 0.75 THRA (0.50) PDCD1CD274THRBTHRAPPARG
SCHEMBL268942 0.74 PKM (0.58) PTPN1SLC1A5THRBMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319096-B2 Thyroid hormone receptor antagonists for cardiac and metabolic disorders II KARO BIO AB (SE) 2008-01-15 US claimed
US-20040220147-A1 Thyroid hormone receptor antagonists for cardiac and metabolic disorders ll KARO BIO AB (SE) 2004-11-04 US claimed
EP-1387825-A1 THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC & METABOLIC DISORDERS II KARO BIO AB (SE) 2004-02-11 EP claimed
WO-2002092550-A1 THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC AND METABOLIC DISORDERS II KARO BIO AB (SE) 2002-11-21 WO claimed
US-7319096-B2 Thyroid hormone receptor antagonists for cardiac and metabolic disorders II KARO BIO AB (SE) 2008-01-15 US disclosed
US-20040220147-A1 Thyroid hormone receptor antagonists for cardiac and metabolic disorders ll KARO BIO AB (SE) 2004-11-04 US disclosed
EP-1387825-A1 THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC & METABOLIC DISORDERS II KARO BIO AB (SE) 2004-02-11 EP disclosed
WO-2002092550-A1 THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC AND METABOLIC DISORDERS II KARO BIO AB (SE) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220147-A1 Thyroid hormone receptor antagonists for cardiac and metabolic disorders ll TSHR, TRHR, THRA PTPN1 619/4885PDCD1 3128/4885CD274 2029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.